Abstract:Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in multiple cancers. However, durable antitumor responses have been observed in only a minority of patients, indicating the presence of other inhibitory mechanisms that act to restrain anticancer immunity. Therefore, new therapeutic strategies targeted against other immune suppressive mechanisms are needed to enhance anticancer immunity and maximize the clinical benefit of CIT in patients who are resistant to immune checkpoint inhibition. Preclinical and clinical studies have identified abnormalities in the tumor microenvironment (TME) that can negatively impact the efficacy of PD-1/PD-L1 blockade. Angiogenic factors such as vascular endothelial growth factor (VEGF) drive immunosuppression in the TME by inducing vascular abnormalities, suppressing antigen presentation and immune effector cells, or augmenting the immune suppressive activity of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. In turn, immunosuppressive cells can drive angiogenesis, thereby creating a vicious cycle of suppressed antitumor immunity. VEGF-mediated immune suppression in the TME and its negative impact on the efficacy of CIT provide a therapeutic rationale to combine PD-1/PD-L1 antibodies with anti-VEGF drugs in order to normalize the TME. A multitude of clinical trials have been initiated to evaluate combinations of a PD-1/PD-L1 antibody with an anti-VEGF in a variety of cancers. Recently, the positive results from five Phase III studies in non-small cell lung cancer (adenocarcinoma), renal cell carcinoma, and hepatocellular carcinoma have shown that combinations of PD-1/PD-L1 antibodies and anti-VEGF agents significantly improved clinical outcomes compared with respective standards of care. Such combinations have been approved by health authorities and are now standard treatment options for renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. A plethora of other randomized studies of similar combinations are currently ongoing. Here, we discuss the principle mechanisms of VEGF-mediated immunosuppression studied in preclinical models or as part of translational clinical studies. We also discuss data from recently reported randomized clinical trials. Finally, we discuss how these concepts and approaches can be further incorporated into clinical practice to improve immunotherapy outcomes for patients with cancer.

PDGF-CC Underlies Resistance to VEGF-A Inhibition and Combinatorial Targeting of Both Suppresses Pathological Angiogenesis More Efficiently

PDGF-CC Blockade Inhibits Pathological Angiogenesis by Acting on Multiple Cellular and Molecular Targets.

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Tumor Resistance to Anti-Vegf Therapy Through Up-Regulation of Vegf-C Expression

Therapeutic Paradigm Of Dual Targeting Vegf And Pdgf For Effectively Treating Fgf-2 Off-Target Tumors

Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

Combination of Vascular Endothelial Growth Factor Receptor/platelet-Derived Growth Factor Receptor Inhibition Markedly Improves the Antiangiogenic Efficacy for Advanced Stage Mouse Corneal Neovascularization

HER2-targeted Tumor immunotherapy

Profiling Analysis of Histone Modifications and Gene Expression in Lewis Lung Carcinoma Murine Cells Resistant to Anti-VEGF Treatment

OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: A reversible phenomenon

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

An Interleukin-17–Mediated Paracrine Network Promotes Tumor Resistance to Anti-Angiogenic Therapy

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b.

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Vegf-B Is Dispensable For Blood Vessel Growth But Critical For Their Survival, And Vegf-B Targeting Inhibits Pathological Angiogenesis

New Insights into Antiangiogenic Therapy Resistance in Cancer: Mechanisms and Therapeutic Aspects